MedTrace Logo

Study Of Remission In Patients Treated For Generalized Anxiety Disorder

NCT01788553 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 750

Last updated 2022-05-03

No results posted yet for this study

Summary

The aim of the study is to assess the remission rates in patients treated for generalized anxiety disorder in primary and specialized care. Factors that may influence remission such as disease history and severity of the anxiety disorder, the type of treatment, the presence of co-morbid depression or anxiety disorder as well as socio-demographic factors will also be evaluated. The study will also assess patient functioning and compare functioning in patients who do and do not achieve remission.

Conditions

  • Anxiety Disorders

Interventions

OTHER

remission prevalence of generalized anxiety disorder

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2006-03-31
Completion
2007-03-31
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01788553 on ClinicalTrials.gov